作者: TCMFINDER 2021-09-20 09:35:00
Abstract for Reference 6: Treatment of androgeneticalopecia in men6TIFinasteride in the treatment of men with frontal male pattern hair loss.AULeyden J, Dunlap F, Miller B, Winters P, Lebwohl M,Hecker D, Kraus S, Baldwin H, Shalita A, Draelos Z, Markou M, Thiboutot D, Rapaport M, Kang S, KellyT, Pariser D, Webster G, Hordinsky M, Rietschel R,Katz HI, Terranella L, Best S, Round E, Waldstreicher JSOJ Am Acad Dermatol. 1999;40(6 Pt 1):930.BACKGROUND: Finasteride, a specific inhibitor of type II 5alpha-reductase, decreases serum and scalp dihydrotestosterone and has been shown to be effective in men with vertex male pattern hair loss.OBJECTIVE: This study evaluated the efficacy of finasteride 1 mg/day in men with frontal (anterior/mid) scalp hair thinning.METHODS: This was a 1-year, double-blind, placebo-controlled study followed by a 1-year open extension. Efficacy was assessed by hair counts (1 cm2 circular area), patient and investigator assessments, and global photographic review.RESULTS: There was a significant increase in hair count in the frontal scalp of finasteride-treated patients (P<.001), as well as significant improvements in patient, investigator, and global photographicassessments. Efficacy was maintained or improved throughout the second year of the study. Finasteridewas generally well tolerated.CONCLUSION: In men with hair loss in the anterior/mid area of the scalp, finasteride 1 mg/day slowed hair loss and increased hair growth.ADUniversity of Pennsylvania School of Medicine, Philadelphia, USA.PMID10365924
作者: TCMFINDER 2021-09-23 14:00:00
文獻裡面有很多知識喔書中自有黃金屋Abstract for Reference 1: Treatment of androgeneticalopecia in men1TIThe effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.AUAdil A, Godwin MSOJ Am Acad Dermatol. 2017;77(1):136. Epub 2017 Apr 7.BACKGROUND: Androgenetic alopecia, or male patternhair loss, is a hair loss disorder mediated by dihydrotestosterone, the potent form of testosterone.Currently, minoxidil and finasteride are Food andDrug Administration (FDA)-approved, and HairMax LaserComb, which is FDA-cleared, are the only treatments recognized by the FDA as treatments of androgenetic alopecia.OBJECTIVE: This systematic review and meta-analysisassesses the efficacy of nonsurgical treatments ofandrogenetic alopecia in comparison to placebo forimproving hair density, thickness, growth (definedby an increased anagen:telogen ratio), or subjective global assessments done by patients and investigators.METHODS: A systematic review of randomized controlled trials was conducted. PubMed, Embase, and Cochrane were searched up to December 2016, with no lowerlimit on the year. We included only randomized controlled trials of good or fair quality based on theUS Preventive Services Task Force quality assessment process.RESULTS: A meta-analysis was conducted separately for 5 groups of studies that tested the following hair loss treatments: low-level laser light therapy in men, 5% minoxidil in men, 2% minoxidil in men, 1mg finasteride in men, and 2% minoxidil in women.All treatments were superior to placebo (P < .00001) in the 5 meta-analyses. Other treatments were not included because the appropriate data were lacking.LIMITATIONS: High heterogeneity in most studies.CONCLUSIONS: This meta-analysis strongly suggests that minoxidil, finasteride, and low-level laser light therapy are effective for promoting hair growthin men with androgenetic alopecia and that minoxidil is effective in women with androgenetic alopecia.ADMemorial University of Newfoundland, St. John's, Newfoundland.PMID28396101